Waldenstrom's macroglobulinemia: Treatment ideas
By Steve Kirsch
August 11, 2007
Abstract
In July 2007, I was diagnosed with a rare incurable blood cancer. I have
slightly more than 5 years left. This page describes what I'm doing to try to
save my life and the lives of others with this disease.
First, a very short course in hematology. Blood is composed of a yellowish
liquid called plasma, red cells (which are the majority of cells which is why
blood appears red), white cells, platelets (used for clotting). There are 5
different kinds of white cells: neutrophils, monocytes,
lymphocytes, eosinophils and basophils. In turn, there are three major types of
lymphocytes: T cells, B cells (aka B-lymphocytes), and natural killer (NK)
cells. B-cells, which are created in your bone marrow, are critical to your
immune system since it is these cells that produce antibodies that fight off
disease. Each B-cell has a unique receptor protein (known as the BCR) on its
surface that will bind to one particular antigen (an antigen is a molecule that
stimulates an immune response). Once a B-cell encounters its cognate antigen and
receives an addition signal from a T helper cell (this is ususally, but not
always required), it will then differentiate either into a relatively short
lived plasma B cell (aka plasma cell) or a long living memory B cell. In this
disease, we are interested in the former: the plasma cell. So plasma cells are
large B cells that have been exposed to an antigen and are now secreting large
amounts of antibodies in order to attack and destroy an enemy (whereas before
activation, the B-cells only express surface bound IgM). In WM, it is these
plasma cells which multiply out of control and produce excessive amounts of the
IgM antibody class. There are 5 different classes of antibodies: IgA, IgD, IgE,
IgG, and IgM; the IgM class antibodies are produced quickly and in high volume
when a pathogen occurs and before IgG take over the longer term work of
destroying the pathogen. These diseased plasma cells invade your bone marrow and
other parts of your body. For example, one person unable to walk, reported two
tumors in their foot and a PET scan, then MRI, then biopsies revealed their heel
bone and soft tissue tumors were all completely infiltrated with WM cells.
The only good news in all of this is that if my body
becomes infected with the one specific disease that matches my antibodies, I'm
completely immune because I have more defenses against this one disease than
anyone else on the planet. The bad news is there is no way to tell what I'm
immune to! Each person with WM is immune to something different.
Our first step is to figure out what is different about these B-cells.
Because a bone marrow transplant from a human into a mouse induced the disease, it probably
means that there isn't something external to the the bone marrow that triggers
the disease. However, we can't totally rule that out because it could be that
the original triggering mechanism lies outside the bone marrow and then, one
triggered, the disease is self-sustaining through multiplication of somatic
cells. The cause therefore is one of four
things:
- the B-cells themselves are created with a genetic defect (e.g., because
the stem cells or other B-cells that create the B-cells are also defective or that the stem
cell is told by some outside force to create a genetically defective
B-cell),
- the B-cells are genetically perfect, but there is either an antigen or
something elsewhere in the bone marrow such as a mast cell that is sending
instructions into those B-cells to make or allow them to produce high IgM
antibodies
- the B-cells were created without any genetic defects, but something
external to the cell changed them during the maturation process so they are
now genetically defective
- one or more of the above
There are many papers such as
Gene
expression profiling of B lymphocytes and plasma cells from Waldenstrom's
macroglobulinemia indicates that WM B-cells are indeed genetically
different. Deletion of the long arm of chromosome 6 is the
most common cytogenetic abnormality found in WM. Therefore, it must mean
that at least 1 or 3 is true, i.e., either the cells were born with a genetic
defect or they "developed" their defects after birth. But just because these
cells are
genetically different, it doesn't necessarily mean that the genetic difference
is the cause of the problem. That's the natural conclusion, but you cannot rule
out the possibility that each of the genetic differences are all completely benign (or that it
just creates a "susceptibility" to some molecule that is normally present in the
blood) and that there is a "mystery antigen" that is causing the IgM flareup.
Our next step is determine, if it is a defect, whether it is "at cell birth" or an
"acquired" defect that happens after a perfect B-cell is born. I'm not sure how you do that, but there must be a way. This
step may not be required but it might be helpful in eliminating treatment
options.
Next, we need to understand whether it is the sheer number of plasma cells
that is the problem, or that the number of plasma cells is normal but they are
just secreting IgM much faster than normal. My best understanding from the
papers is that the abnormal plasma cells do not die (normal plasma cells don't
live very long).
Then we need to understand whether these IgM antibodies all look alike or are
they different?
Once we have an understanding of how the disease operates, our last step is
to determine what the best treatment path is. There are at least 16
possible treatments avenues to consider that I can think of off the top of my head:
- repair the genetic defects in the circulating B-cells, e.g., gene
therapy
- kill just the defective B-cells, e.g., something like
Rituxan (which unfortunately kills
both the defective and healthy B-cells since both exhibit positive CD20)
- Prevent the defective B-cells from being created, e.g., it's possible
(but unlikely) that the stem cells that create the B-cells are perfect and
that there is some environmental factor that causes the perfect stem cell to
create a defective B-cell either when it is first created or sometime during
the recombination/maturation process of the B-cell. Drugs such as
Belimumab prevent the
creation of all B-cells, rather than just the defective B-cells which is
what we want.
- fix the defective stem cells so they no longer creates defective
B-cells, e.g., gene therapy or SCT
- kill the defective stem cells so that defective B-cells will no longer
be created
- destroy the IgM that gets created by the defective B-cells (this may be
completely useless other than reducing serum viscosity)
- remove or somehow neutralize the mystery antigen that is stimulating the
B-cells to produce IgM (assuming there is such a mystery antigen)
- inject something that will bind to the defective B-cells and keep them
busy until they are dead so that they do not produce IgM.
- Get rid of the supporting infrastructure or inhibit communication with
cells (such as
bone marrow
mast cells) that are enabling the support of lymphoplasmacytic cell growth.
In any cancer, the cells need a support structure in order to support the
higher than normal growth. Also, there may be some kind of signaling
mechanism that tells these defective cells to grow. If you can either remove
the guy sending the signals, or inhibit the signals from reaching the
receiver, you may be able to stop the growth of the cancer. Similarly, there
may be cells or other supporting infrastructure that the cancer cells need
to survive and multiply. In traditional cancers, for example, the cancer
needs to grow excess blood vessels in order to supply the evil troops with
food. So if you can cut off the energy supply to the malignant cells, they
will die of starvation or neglect.
- understand why the body develops resistance to the existing chemo treatment and
circumvent it so that treatments may be repeated as necessary to keep things
under control. This likely isn't a very viable strategy for at least two
reasons: 1) if this was easy, we'd have antibiotics that people don't
develop a resistance to and 2) the more stress you
put healthy organs under, the greater the chance they will fail on the next
treatment.
- Prevent the defective B-cells from replicating (currently, I don't
understand whether the stem cells create all the B-cells or whether the stem
cells create some B-cells and those B-cells replicate or both)
- Cut short the normal lifespan of the defective B-cells, i.e., so that
they die sooner than the life of a normal B-cell
- Prevent the defective B-cell from living an extended life (this assumes
the defective B-cells live longer than normal B-cells or replicate forever
or replicate at a more rapid rate than normal)
- Reduce the number of replications of the defective cells, e.g., either
entirely prevent the defective cell from replicating itself or do something
that impedes the defective cells from replicating out of control either by
slowing down the rate of replication or the total number of offspring.
- Figure out a way to make more IgM cells class switch into some other
class such as IgG. I have no idea if this would be effective; if you could
do it, it would be much more of a treatment than a cure and it isn't clear
that the cure would actually be an improvement.
- If the B-cell is T-cell dependent, then if you can stop the T cell from
helping out a diseased B-cell, the plasma cell will not be created. On the
other hand, if the T-cells are the problem because they are defective and
when a defective T-cell activates a B-cell to create a defective plasma
cell, then we need to understand that more.
And here are some things I'd like to understand better:
- Is the disease is due to oncogenes that have been turned on or by tumor
suppressor genes that have been turned off?
- There are many DNA changes in WM cells. Which one(s) are significant, if
any?
- How important is the excess production of interleukin-6 (by the
dendritic cells in the bone marrow) to the disease? Is reducing the IL-6
production effective in slowing WM?
|